What is HC Wainwright’s Estimate for Innoviva Q4 Earnings?

Innoviva, Inc. (NASDAQ:INVA) – HC Wainwright cut their Q4 2026 EPS estimates for Innoviva in a research report issued on Monday, June 22nd. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will post earnings of $0.54 per share for the quarter, down from their prior estimate of $0.55. HC Wainwright has a “Buy” rating and a $46.00 price target on the stock. The consensus estimate for Innoviva’s current full-year earnings is $2.23 per share. HC Wainwright also issued estimates for Innoviva’s Q1 2027 earnings at $0.51 EPS, Q2 2027 earnings at $0.61 EPS, Q3 2027 earnings at $0.59 EPS, Q4 2027 earnings at $0.66 EPS and FY2027 earnings at $2.36 EPS.

Innoviva (NASDAQ:INVA) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.01. The company had revenue of $97.99 million for the quarter, compared to analyst estimates of $101.57 million. Innoviva had a net margin of 119.89% and a return on equity of 33.33%.

A number of other research analysts have also weighed in on the stock. BTIG Research reaffirmed a “buy” rating and issued a $42.00 price target on shares of Innoviva in a research note on Monday. Wall Street Zen raised shares of Innoviva from a “hold” rating to a “buy” rating in a research report on Saturday, June 6th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Innoviva in a report on Friday, March 27th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $36.20.

Innoviva Trading Up 0.8%

NASDAQ:INVA opened at $22.67 on Tuesday. The business’s 50-day simple moving average is $22.75 and its 200-day simple moving average is $21.84. Innoviva has a fifty-two week low of $16.52 and a fifty-two week high of $25.15. The company has a debt-to-equity ratio of 0.19, a current ratio of 21.13 and a quick ratio of 20.07. The stock has a market capitalization of $1.67 billion, a PE ratio of 3.77 and a beta of 0.35.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of INVA. Parallel Advisors LLC boosted its position in shares of Innoviva by 82.8% in the first quarter. Parallel Advisors LLC now owns 1,179 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 534 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in shares of Innoviva by 297.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,398 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 1,795 shares in the last quarter. Danske Bank A S bought a new position in Innoviva in the third quarter valued at about $55,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Innoviva by 49.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,633 shares of the biotechnology company’s stock valued at $73,000 after purchasing an additional 1,197 shares during the last quarter. Finally, Lazard Asset Management LLC bought a new stake in Innoviva during the 2nd quarter worth $92,000. 99.12% of the stock is owned by institutional investors.

About Innoviva

Innoviva, Inc, incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin?out transaction in 2014, separating the royalty assets from a research?based biopharmaceutical enterprise to create a specialized investment vehicle.